From Barchart: 2025-05-22 16:53:00

Shares of Hims & Hers Health dropped 6.3% after Cigna Group’s Evernorth division set a $200 monthly price cap on weight-loss meds, impacting drug market pricing. Hims & Hers faces direct competition with compounded Semaglutide and GLP-1 treatments. The stock closed at $53.52, down 7.7% from earlier. The market views this news as significant but not altering its perception of the business, given the stock’s high volatility. Recent strong Q1 results led to a 20.2% gain 16 days ago, with sales doubling year-over-year. Despite softer revenue guidance, the stock is up 112% year-to-date but still below its 52-week high.

Investors who bought $1,000 of Hims & Hers Health 5 years ago would now see an investment worth $5,340. The Gorilla Game principles suggest enterprise software stocks with generative AI capabilities could be future leaders. A free report on a promising enterprise software stock is available for interested investors.



Read more at Barchart: Why Hims & Hers Health (HIMS) Stock Is Falling Today